10x Genomics lifted its FY2026 revenue outlook to $610‑$630 million, up to $10 million from the prior $600‑$625 million range. The higher target reflects modest top‑line growth and bolsters confidence in the company’s single‑cell platform demand, supporting its valuation despite a recent loss.

Key Highlights

  • Gross margin rose to 74% from 72% YoY, helped by $2.6 million tariff refunds
  • Operating expenses jumped 39% to $132.1 million, driven by lower settlement gain
  • The margin expansion to 74% underscores the firm’s improved cost structure, with manufacturing efficiencies offsetting the loss of non‑recurring licensing revenue.

The company also posted second‑quarter revenue of $151.0 million, a 3% increase when stripped of a $1.6 million litigation settlement, while earnings per share came in at a loss of $‑0.14 versus a consensus estimate of $‑0.25. The guidance lift signals confidence in the firm’s expanding single‑cell and spatial platforms, which support its long‑term growth trajectory.

Revenue Guidance Upgrade

Management framed the increase as a “unique positioning” to capture emerging diagnostic opportunities, emphasizing that the growth is modest, between 2% and 5% over the prior year, yet meaningful in a market where comparable firms such as BIO and RGEN show little movement. The upgraded guidance aligns with the firm’s strategic push into multi‑omics, a sector poised for accelerated adoption. Investors will view the tighter range as a sign that cash flow visibility is improving, even as the firm navigates a quarterly loss.

Q2 Financial Snapshot

Quarterly revenue of $151.0 million marked a decline from $172.9 million in the same period a year earlier, yet when the $1.6 million litigation settlement is removed, revenue stands at $149.4 million, indicating a 3% year‑over‑year rise on a comparable basis. Operating expenses surged to $132.1 million, a 39% increase driven by a sharp drop in settlement gains, from a $40.7 million credit in 2025 to a $3.4 million gain this quarter. The operating loss of $19.6 million contrasts with $30.1 million of operating income a year prior, highlighting the financial impact of reduced one‑off gains.

Margin and Expense Dynamics

The margin expansion to 74% underscores the firm’s improved cost structure, with manufacturing efficiencies offsetting the loss of non‑recurring licensing revenue. Despite higher expenses, the flat year‑over‑year operating spend, after adjusting for settlement impacts, suggests that the core cost base is stabilizing. Net loss widened to $17.9 million from a profit of $34.5 million in the prior year, reflecting the combined effect of lower settlement income and higher spending on research and development, $56.8 million versus $61.2 million a year earlier.

The cash position remains strong at $552.0 million, providing ample runway to fund ongoing product development and the recently acquired Proteintech Genomics division.

Forward Outlook

Management’s forward guidance and recent partnership announcements point to a continued emphasis on expanding the single‑cell and spatial biology portfolio. Analysts will scrutinize whether the company can sustain margin improvements while scaling its expense base, setting the stage for the next catalyst in its growth narrative.

Peers Moving on This News

  • Bio Rad Laboratories Inc (BIO) little changed
  • Repligen Corp (RGEN) down 0.4%
  • Avantor Inc (AVTR) little changed

Analysis based on the Form 8-K filed 6 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.